secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001070081-23-000036
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics reports positive interim Phase 2 data for PTC518 in Huntington's disease
--------------------------------------------------------------------------------

- Interim data from PIVOT-HD Phase 2 study shows dose-dependent lowering of HTT protein in blood, with mean 30% reduction at 10mg dose.
- PTC518 treatment well tolerated; no treatment-related serious adverse events or dose-limiting toxicities reported.
- No CSF NfL treatment-related spikes; trend towards lowering of CSF NfL levels after 12 weeks.
- Conference call held June 21, 2023 at 8:00 AM EDT to discuss data; slides furnished as Exhibit 99.2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000036/0001070081-23-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000036/tmb-20230621x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-23-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer